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Abstract
Spontaneous schwannomas were detected by mag-
netic resonance imaging (MRI) in a transgenic murine
model of neurofibromatosis type 2 (NF2) expressing a
dominant mutant form of merlin under the Schwann
cell–specific P0 promoter. Approximately 85% of the
investigated mice showed putative tumors by 24
months of age. Specifically, 21% of the mice showed
tumors in the intercostal muscles, 14% in the limb
muscles, 7% in the spinal cord and spinal ganglia, 7%
in the external ear, 14% in the muscle of the
abdominal region, and 7% in the intestine; 66% of
the female mice had uterine tumors. Multiple tumors
were detected by MRI in 21% of mice. The tumors
were isointense with muscle by T1-weighted MRI,
showed strong enhancement following administration
of gadolinium-DTPA, and were markedly hyperintense
by T2-weighted MRI, all hallmarks of the clinical
manifestation. Hematoxylin and eosin staining and
immunohistochemistry indicated that the tumors con-
sisted of schwannomas and Schwann cell hyper-
plasias. The lesions stained positively for S-100
protein and a marker antigen for the mutated trans-
genic NF2 protein, confirming that the imaged tumors
and areas of hyperplasia were of Schwann cell origin
and expressed the mutated NF2 protein. Tumors were
highly infectable with a recombinant herpes simplex
virus type 1 vector, hrR3, which contains the reporter
gene, lacZ. The ability to develop schwannoma growth
with a noninvasive imaging technique will allow as-
sessment of therapeutic interventions.
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Introduction
Neurofibromatosis type 2 (NF2) is an autosomal dominantly
inherited genetic disorder characterized by neoplastic and
dysplastic lesions of Schwann cells (schwannomas and
schwannosis), meningeal cells (meningiomas and meningio-
angiomatosis), and glial cells (gliomas and glial microhamar-
tomas) [1]. Patients often develop multiple schwannomas,
spinal cord schwannomas, and/or cutaneous schwannomas
in the periphery, and meningiomas and astrocytomas/
ependymomas in the brain [2–4]. In this condition, usually
germ line mutations of one allele of this gene [5] combined
with somatic mutations of the other allele lead to functional
loss of the encoded protein, termed merlin [6 ] or schwanno-
min [5], with consequent loss of growth regulation of some
cells, e.g., Schwann cells. Most of the germ line and somatic
mutations in the NF2 gene result in either a stop codon, a
splicing alteration, or a frameshift, leading to the production of
a truncated protein [7,8]. In addition, in - frame deletions and
missense mutations have also been found, suggesting that
mutation of particular functional domains can also abolish the
function of the NF2 protein. Inactivation of the NF2 protein
product occurs in both sporadic and familial schwannomas
and meningiomas, supporting the NF2 gene as a tumor
suppressor gene [9–13].
The NF2 protein is a member of the ezrin, radixin, moesin
(ERM) family of cytoskeleton/membrane linker proteins
[5,6]. Endogenous merlin is localized to the plasma
membrane of Schwann and other cell types [14]. When
transiently expressed in various cell types, some mutant NF2
proteins corresponding to naturally occurring human muta-
tions demonstrate abnormal cellular localization [15,16]. For
example, whereas carboxy terminal deletion mutants remain
localized at cell membrane, mutants with intact carboxy
terminal but deleted or altered amino terminal domains
relocalize to the perinuclear cytoplasmic region. Relocaliza-
tion to the cytoplasm was also observed for a mutant protein
modeled from naturally occurring human NF2 mutation
in which exons 2 to 3 are spliced out without a frameshift
Sch-(39–121) [17].
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Schwannoma and meningioma tumors form in NF2
patients by overgrowth of cells, which support neurons in
the nervous system. Although rarely becoming malignant,
schwannomas and meningiomas associated with NF2 can
severely compromise neural function leading to paralysis,
deafness, and death through compression of critical brain
nerves and structures [18] or blockade of cerebrospinal
fluid (CSF) flow [19]. In NF2, the most severe and life -
threatening tumors are usually those at the skull base. They
may be cranial nerve schwannomas (e.g., some vestibular
schwannomas are inoperable) or skull base meningiomas,
which, due to their size or multiplicity, are not surgically ac-
cessible. In fact, the cause of death of many NF2 patients is
progressive brainstem compression from such tumors, and
death occurs, on average, 15 years after diagnosis of such
lesions [20]. Other clinical problems in need of new ther-
apeutic intervention are multiple meningiomas and spinal
cord tumors. Repeated resection of tumor material can be
performed, but after several craniotomies, the patients are
left so debilitated that further surgery is not helpful.
These types of tumors are appropriate targets for gene
therapy in its present state of development, as they grow
slowly, remain localized to focal areas of the body, and can be
readily pinpointed with magnetic resonance imaging (MRI).
The humane advantages of this type of therapy are that it is
carried out by direct injection of tumor masses, and that the
vectors, transgene products, and prodrugs have essentially
no toxicity to normal tissue, and hence should have minimal
morbidity to patients. The overall goal of our project involves
directing and evaluating gene delivery to these types of
tumors in animal models using minimally invasive imaging
methods and vectors applicable to future human use.
Although still in its infancy, gene therapy has the potential
to serve as an adjunct to current therapies. For treatment of
benign tumors, a number of therapeutic transgenes can be
employed, such as those encoding prodrug activation
enzymes demonstrated to arrest growth and reduce volume
[21,22]. Two important components to the development of
this promising technology are: 1) animal models that form
spontaneous tumors of the same genetic etiology and same
cellular type as found in humans; and 2) imaging modalities
that will allow detection of lesions and monitoring of gene
delivery and therapeutic efficacy in living animals. The
strategic advantage of NF2, in this regard, is that a mouse
model exists, which parallels the human condition, and the
lesions are usually focal and can be readily pinpointed with
MRI, which allows direct targeted injection of tumor masses.
MRI is able to noninvasively provide information regarding
tumor metabolism and pathophysiology. Because MRI can
provide information about in vivo tumor metabolism and
pathophysiology nondestructively, preclinical results from
animal models may be applied in clinical settings [23]. Based
on extensive experimental /preclinical and clinical studies of
gene therapy for gliomas [24–28], NF2 lesions, due to their
benign and focal nature, appear to be a realistic target for
gene therapy.
In this study, we have used a transgenic murine model for
NF2, which employs heterozygous mice expressing the
mutant Sch-(39–121) ( line 27) NF2 protein, similar to that
found in some NF2 patients, in Schwann cells under the P0
promoter [29]. The mutated transgene consists of an
interstitial deletion of amino acids 39 to 121 in the amino-
terminal domain of human NF2 cDNA. Previous pathologic
analyses of these transgenic mice have demonstrated a high
incidence of Schwann cell–derived tumors and Schwann
cell hyperplasia in older animals at the time of sacrifice. In
particular, the average age of tumor incidence in these P0-
Sch-(39–121) transgenic mice was 17.5 months. Macro-
scopic tumors were found in the uterus of 8 of 20 female
transgenic mice between the age of 13 and 20.5 months,
whereas microscopic foci of Schwann cell proliferation
(schwannosis) were detected in muscle and spinal ganglia
as early as 6 and 9 months, respectively [29].
The aims of this particular study were to determine if
schwannomas found in these transgenic mice could be
detected with MRI, and to evaluate whether these schwan-
nomas were infectable with herpes simplex virus (HSV) viral
vectors. The HSV virion is one of the most efficient gene
transfer vehicles for central nervous system–derived cells,
such as brain tumors [30]. We have detected schwannomas
in these mice using MRI and correlated this with histochem-
ical and immunocytochemical analysis. We have also
demonstrated infectability in these schwannomas with




Fourteen transgenic mice (11 males and 3 females),
ages 13 to 20 months, were used for this study. These
[P0-Sch-(39–121) ] transgenic mice express a mutant
form of merlin with an in- frame interstitial deletion in the
amino terminal domain of NF2 under the P0 promoter [29].
Mice were genotyped by isolating tail DNA using the
DNeasy Tissue Kit (Cat no. 69506; Qiagen, Valencia, CA).
PCR was performed on the purified tail DNA using the
forward primer GAP 3.3: 50 -AGATACTGACATGAAGCGG-
30 and the reverse primer TAG antisense: 50 -TTACTTGCC-
CAGCCGGTTCAT-30. A 320-bp fragment represents the
mutant NF2 transgene and no band is detected in wild- type
FVBNmice (WT). A 320-bp band was found in all transgenic
animals when PCR was performed with these primers and
tail DNA, whereas no band is present in this PCR reaction
with tail DNA from a nontransgenic wild - type mouse.
To detect transgene-specific expression, the mutant
protein was tagged with a vesicular stomatitis virus (VSV)
glycoprotein G epitope [29,31]. The 11 carboxy- terminal
amino acids from the VSV-G, preceded by a proline-rich
secondary structure breaker (GPPGP), were linked in-
frame to the carboxyl terminus of the deletion mutant. The
mutated fusion protein can be detected with antibodies
raised against the tag corresponding to the carboxy- terminal
end of the glycoprotein G (see Immunostaining section
below for specifics on the VSV-G antibody).
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MRI
MRI was employed to localize spontaneous schwannoma
tumors. Imaging was performed using a 1.5-T clinical
imaging system (System 5X; General Medical Systems,
Milwaukee, WI) using a 3- in. surface coil. Anesthesized
animals were taped to a Plexiglass plate, and were
positioned immediately below the surface coil. Imaging
sequences included conventional T1-weighted sequences
(TR/TR: 300/11 milliseconds) with and without fat sup-
pression and T2-weighted turbo spin echo sequence (TR/
TE 3000/100 milliseconds) with and without fat suppression.
The field of view was 8 cm, the slice thickness 1.5 mm, and
the imaging matrix was 512192, yielding a voxel dimension
of 1564161500 m. It was anticipated that peripheral
nerve Schwann cell hyperplasias and schwannomas would
appear hyperintense on T2-weighted sequences. For this
reason, an initial study was performed to optimize the type of
T2-weighted sequence (spin echo versus fast spin echo
versus gradient echo). All animals received an intravenous
injection of contrast agent gadolinium (Gd)-DTPA and
dynamic imaging was performed for enhanced detection of
lesions. To correlate the MRI with the presence and size of
tumors, necropsy and careful correlative histology were
performed.
Histology
Those animals that had tumors, as diagnosed by MRI,
were sacrificed by exposure to CO2 and underwent
necropsy. Tumors were removed from animals and placed
in 10% formalin in phosphate-buffered saline (PBS) for
24 hours prior to being dehydrated in graded solutions of
alcohol and xylene and embedded in paraffin [32]. After
embedding, 6-m sections were cut with a Jung Histocat
microtome (Leica, Nussloch, Germany), and mounted on
charged and precleaned Fisher Biotech Probe on Plus
Microscope slides (Fisher Scientific, Pittsburgh, PA). Slides
were incubated at 658C for 1 hour. For hematoxylin and
eosin (H&E) staining, tissue sections on slides were
deparaffinized in xylene for 10 minutes, hydrated in a series
of ethanol solutions (100%, 90%, 70%) for 3 minutes each,
rinsed in PBS for 2 minutes, stained with hematoxylin for
2 minutes, and then rinsed in distilled water until excess
stain was removed. Tissue sections were then dipped in an
eosin solution two to three times, and rinsed in distilled water
until excess stain was removed. Tissue sections were
dehydrated in a series of ethanol solutions (70%, 90%,
Table 1. Distribution of Tumors as Detected by MRI.
Strain P0 -Sch -( 39–121 )
N (M:F ) 11:3
Location of tumor
Spinal cord and ganglia 7% (1 / 14 )
Intercostal muscles 21% (3 /14 )
Limb muscles 14% (2 /14 )
Uterus 67% (2 /03 )
Intestine 7% (1 / 14 )
Stomach 0% (0 / 14 )
Pancreas 0% (0 / 14 )
External ear 7% (1 / 14 )
Muscle in abdominal region 14.2% (2 /14 )
Spinal ganglia and /or muscle 86% (12 / 14 )
Figure 1.MRI of multiple intramuscular tumors in a NF2 dominant mutant transgenic mouse. An anesthesized transgenic male mouse (age 18months ) was taped to
a Plexiglass plate, which was positioned immediately below a 3 - in surface coil. MRI detected a lesion in the right forelimb (arrows in A–C) and a lesion in
intercostals muscles (arrows in D–F ). These lesions were displayed as isointense on T1 -weighted images (A and D), and hyperintense on fat - saturated T2 -
weighted image (B and E). The lesion in the intercostals muscle showed strong enhancement on Gd -DTPA enhanced T1 -weighted image (F ), while the lesion in
the right forelimb showed only slight enhancement after administration of Gd -DTPA (C ).
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100%) for 3 minutes each, and then incubated in xylene for
1 minute prior to being coverslipped with Permount.
Immunostaining
For immunostaining of tissue sections, tissue was
deparaffinized and hydrated by being incubated in xylene
for 15 minutes, 100% ethanol for 3 minutes, 95% ethanol for
3 minutes, 75% ethanol for 3 minutes, 50% ethanol for
3 minutes, and then rinsed in PBS twice for 3 minutes each.
Tissue sections were then permeabilized in 0.5% Triton X in
PBS for 10 minutes, and treated with blocking buffer (5%
goat serum in 1% BSA diluted in 1 PBS) for 30 minutes.
Two polyclonal primary antibodies, rabbit anti–cow S100
(Dako, Glostrup, Denmark) and anti–VSV-G tag (Medical
and Biological Laboratories, Naka-ku, Nagoya, Japan) were
diluted 1:200 in blocking buffer (5% goat serum in 1% BSA
diluted in 1 PBS) and then applied to tissue sections for
1 hour at 378C. Following the primary antibody incubation,
tissue was washed four to six times with blocking buffer. For
the S-100 protein staining, the secondary antibody goat
anti–rabbit IgG-Cy3 (Jackson Immuno Research Labora-
tories, West Grove, PA) was applied to tissue at a dilution of
1:200 for 30 minutes at room temperature. For VSV-G
staining, the secondary antibody goat anti–rabbit IgG-FITC
(Biosource International, Camarillo, CA) was applied to
tissue at a dilution of 1:200 for 30 minutes at room
temperature. Following incubation in the secondary anti-
body, tissues were rinsed four to six times in 1% BSA and
mounted with glass coverslips and fluorescent mounting
medium (cat no. S3023; Dako), prior to being viewed with an
Olympus microscope.
Infection with HSV
The replication-conditional HSV vector, hrR3, has a
deletion in the gene for ribonucleotide reductase ( ICP6)
replaced with lacZ, thereby placing the lacZ under an early
viral promoter [33]. Tumors were injected with hrR3
(2.3108 pfu in 30 l ) and, 3 days later, removed from
the animal, fixed for 24 hours in 4% paraformaldehyde,
then placed in 25% sucrose for several days. Tissue
was then frozen, cut into 40-m sections, and analyzed
by histology for b -galactosidase expression by staining
the sections with X-gal buffer [1 mg/ml 5-bromo-4-
chloro-3- indoxyl b -galactosidase, 5 mM K3Fe(CN)6, 5 mM
K3Fe(CN)6 2 mM MgCl2 in 0.1 M sodium phosphate buffer
(pH 7.4) ] at 378C for 12 hours [34].
Results
Detection of Schwannomas in NF2 Transgenic Mice by MRI
Previous studies had shown that NF2 transgenic [P0-
Sch-(39–121) ] animals typically demonstrate Schwann
cell hyperplasias and/or schwannomas in 80% of animals by
9 months of age, especially in the spinal ganglia and around
peripheral nerve endings in skeletal muscle [29]. In this
study, MRI was conducted on 14 transgenic mice, 13 to






Figure 2. Histopathology and immunostaining for the Schwann cell marker S -100 protein of the tumor from the same mouse, which was imaged by MRI as shown
in Figure 2. H&E staining was performed on paraffin -embedded sections. The tumor was dispersed among the muscle fibers (A, 10; B, 20 ) of the right
forelimb. Schwann cell hyperplasias are also evident within the muscle fibers (C, 50 ). Immunohistochemistry was performed on these tumor sections using a
monoclonal antibody to S -100 protein, which identifies cells of Schwann cell origin. Positive immunostaining was present in paraffin sections from the
intramuscular tumor (D, 40 ), but absent in sections from nontumor skeletal leg muscle (E ), and absent when treated with secondary antibody alone (F, 40 ).
The specific S -100 protein staining of this intramuscular tumor indicates that the tumor is expressing a protein, which is also expressed in Schwann cells and is
consistent with Schwann cell origin. Scale bar=50 m.
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(12/14) of these mice showed tumors by imaging. Specif-
ically, 21% of the mice showed tumors in the intercostal
muscles, 14% in the limb muscles, 7% in the spinal cord and
spinal ganglia, 7% in the external ear, 14% in the muscle of
the abdominal region, and 7% in the intestines; 66% (2/3) of
the female mice had uterine tumors (Table 1). Multiple
tumors were detected by MRI in 21% of mice; for instance,
one male mouse had tumors in the skeletal muscles of both
the limb and rib.
In general, the tumors demonstrated marked hyper-
intensity using the T2W1 fat saturation sequence, were
isointense or hypointense with other organs using the T1W1
spin sequence, showed significant enhancement following
intravenous contrast administration, and were well defined
with a sharp margin. These imaging characteristics are
similar to those observed in schwannomas in human patients
[35–38]. Tumors measured between 3 and 7 mm in length.
All tumors identified by necropsy were also detected by
MRI. However, prospective reading of MRI scans suggested
equivocal findings not confirmed by histology in 7% mice
imaged. Most of these findings were related to volume
averaging artifacts. In 7% of mice that were thought to have
tumors by imaging, no tumors were found by necropsy and
histological examination.
Figure 1 illustrates MRI of a male mouse (age 18
months) that had tumors in the muscles of the right
forelimb (Panels A–C) and in the intercostal muscles
(Panels D–F). Two of three female mice imaged by MRI
had uterine tumors (Figure 2). Using T1W1 imaging, the
tumor displayed isointensity with other organs (Figure 2A ).
Using the T2W1 fat saturation sequence, the uterine tumor
had marked hyperintensity (Figure 2B–D ) and was well
defined with a sharp margin, imaging characteristics similar
to those observed for schwannomas in human patients
[35–38]. An intestinal tumor in one female mouse was
also evident.
Each mouse underwent MRI at least once, and several
mice were imaged up to three times. If the diagnosis of tumor
from MRI was clear -cut, the mice were sacrificed for a
necropsy and histological examination. Whereas the mice
examined in this study were not followed to document tumor
growth over time, future studies will address volumetric
changes of these schwannomas over time and the response
of these tumors to therapeutic treatment.
Characterization of Schwannomas in NF2 Transgenic Mice
Immunohistochemical studies were performed on sec-
tions of tumors from those transgenic mice that had tumors







Figure 3. MRI of a uterine tumor in a NF2 dominant mutant transgenic mouse [P0 -Sch -( 39–121 ) ]. MRI detected a large uterine tumor with a well - defined
margin, which showed isointensity on T1 -weighted image (A ) and hyperintensity on fat - saturated T2 -weighted images (B–D). The fluid collection inside the
uterus was displayed as hypointense on T1 (A ) and hyperintense on T2 -weighted images (B–D). Intestinal distention was marked on both T1 - and T2 -weighted
images, corresponding to an underlying intestinal tumor. Images B–D are 300 m apart, from ventral to dorsal.
Figure 4. Gross anatomy of female NF2 transgenic mouse, which underwent
MRI and is illustrated in Figure 4. A necropsy revealed that this mouse had a
huge uterine tumor ( see black arrow ) and putative tumors in the large
intestine ( see swollen area, blue arrow ) and gut, which were all confirmed by
histology (Figure 5 ).
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indicated by MRI and histological analysis. The Schwann
cell origin of these tumors was examined by staining with
an antibody to S-100 protein, which is a marker for cells of
Schwann cell origin. Immunohistochemistry was performed
using a polyclonal antibody to S-100 protein (Dako,
Carpinteria, CA) on tumor sections from the right forelimb
of the mouse, which was imaged by MRI (Figure 1) and on
sections from the forelimb of a normal mouse. Positive
immunostaining was present in paraffin sections from the
intramuscular tumor (Figure 3D ), but absent in sections of
normal skeletal leg muscle (Figure 3E ) and absent when
incubated with secondary antibody alone (Figure 3F ), sug-
gesting that this intramuscular tumor is a schwannoma.
Likewise, the uterine tumor illustrated in Figures 4 – 6 also
stains positively for S-100 protein. These data indicate that
the tumors detected by MRI and histology in the NF2
transgenic mice P0-Sch-(39–121) are schwannomas.
Other immunohistochemical studies confirm that the tumor
sections are positive for VSV-G, the tag for the mutated
human NF2 transgene (Figure 7). Preliminary experiments
involving histological staining indicate that these schwan-
nomas do not stain for myelin (data not shown), consistent
with previous evidence of disaggregation of myelin sheaths
in vestibular human schwannomas [39].
Infectability of Schwannomas with a Replication-Conditional
HSV Vector
We have also investigated the infectability of these
schwannomas, both in cell culture and in vivo, with the
replication-conditional HSV vector, hrR3, which is capable of
Figure 5. H&E staining of the uterine tumor, which was depicted in Figures 4 and 5. Note that the tissue is hypercellular (more nuclei / unit area than normal ), which is
evident in (A ) (20 ). The nuclei are pleiomorphic ( varying in shape and size ) (B, 100 ). In addition, there are increased numbers of mitotic figures (not evident in
this picture ). Yet the cells still express some of the traits of normal smooth muscles (e.g., bands of red cytoplasm ). One nucleus ( at lower right ) is within a band of red
cytoplasm (B, 100 ). Scale bar=100 m for 20 magnification; 20 m for 100 magnification. Sections from normal mouse uterus are illustrated in (C ) and (D ).
Note the lack of hypercellularity in (C ) (20 ) and the similarity in shape and size of the nuclei at higher power (D, 100 ).
Figure 6. Schwann cell origin of uterine tumor and tumor in gut frommouse depicted in Figures 4, 5 and 6. A polyclonal antibody to S -100 protein was used to detect
cells of Schwann cell origin on paraffin - embedded section. Positive immunostaining was present in the uterine tumor (A, 40 ) and the tumor in the gut. No
immunostaining was present in normal uterine sections (B, 40 ) or in uterine tumor sections with secondary antibody alone, without primary antibody (C, 40 ).
Scale bar=50 m.
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replication only in dividing cells, thereby killing them [26].
Because most cells in the adult nervous system are
nondividing, this cytotoxicity is selective for tumor cells.
hrR3 contains the reporter gene lacZ [33] that facilitates
tracking of vector - infected cells.
Experiments suggest that the schwannomas are highly
infectable with hrR3, both in vivo and in cell culture. For in
vivo studies, we waited for 3 to 5 days following infection of
hrR3 into the tumor to stain for b -galactosidase expression
to allow the virus to replicate in dividing cells. In this study, we
did not try to quantitate the size of tumors infected with hrR3
because they were diffuse in shape and volumetric analysis
was difficult. The tumors were chosen for infection based on
their location, as they were palpable and externally visible,
allowing for targeted injection.
Figure 8 illustrates b -galactosidase expression in tumor
tissue infected with hrR3 3 days following infection (Figure
8A ), compared to the lack of b -galactosidase expression in
tumor tissue, which was not injected with hrR3 (Figure 8B ).
In order to determine if the cells infected with hrR3 were
schwannomas, double staining of tumors infected with hrR3
was also carried out with X-gal staining and immunocy-
tochemistry using an antibody to S-100 protein. Figure 8C
and D illustrates that b -galactosidase expression and
S-100 protein staining share a similar pattern of distribution
in tumor tissue infected with hrR3, suggesting that the
Figure 7. Detection of VSV -Gmarker for mutated NF2 gene in schwannomas fromNF2 transgenic mice. Paraffin sections from the tumors are illustrated in Figure 7,
extracted from the mouse shown in Figure 6, and were immunostained with a polyclonal antibody to VSV -G. Positive staining was present in sections from the
uterine tumor (A, 40 ), but absent in sections from nontumor tissue (B, 40 ) and control sections treated with secondary antibody alone (C, 40 ). Scale
bar=50 m.
Figure 8.  -Galactosidase expression and S -100 protein staining share a similar pattern of distribution in tumor tissue infected with hrR3 (2.3 10 8 pfu ). Three
days after injection of virus into the tumor, tumor tissue was removed from the animal, fixed for 24 hours in 4% paraformaldehyde, then placed in 25% sucrose for
several days. Tissue was frozen, cut into 40 -m sections, and stained with X -gal buffer [ 1 mg /ml 5 -bromo -4 - chloro -3 - indoxyl  - galactosidase, 5 mM
K3Fe(CN )6, 5 mM K3Fe(CN )6, 3H2O, 2 mM MgCl2 in 0.1 M sodium phosphate buffer ( pH 7.4 ) ] at 37 8C for 12 hour.  -Galactosidase expression is present in
tumor tissue infected with hrR3 (A, 40 ), indicating infection with HSV vectors, but absent in tumor tissue that was not injected with hrR3 (B, 40 ). Tissue was
double - stained for the presence of  - galactosidase and the Schwann cell maker S -100 protein.  -Galactosidase present in tumor tissue injected with hrR3 (C,
100 ) shared a similar pattern of distribution with S -100 protein staining (D, 100 ), suggesting that the schwannomas themselves are infectable with hrR3. Scale
bar=50 m for 40 magnification and 20 m for 100 magnification.
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schwannoma cells themselves are infectable with hrR3. In
culture, schwannoma tumor cells infected with hrR3 at an
MOI of 0.5 to 2.0 and fixed 48 hours later stained positively
for b -galactosidase expression, and preliminary evaluation
indicated that the extent of b -galactosidase expression
was proportional to the amount of virus added (data not
shown).
Discussion
Our findings demonstrate that MRI can be used to detect
schwannomas in a transgenic murine model for human NF2.
Histology and immunohistochemistry have confirmed the
Schwann cell origin of these tumors, and expression of the
marker, VSV-G, demonstrates the role of the mutated NF2
transgene in their oncogenesis. The ability to detect these
schwannomas in living animals in a murine model with MRI, a
noninvasive technique, will allow targeting of spontaneous
tumors for treatment. MRI should enable monitoring of
volumetric changes of schwannomas in response to ther-
apeutic interventions, although for some tumors, determi-
nation of tumor volume will be difficult due to their locations
and complex tumor geometry. This opens the way to future
studies in which therapeutic intervention can be tested in this
transgenic murine model of NF2 as preclinical assessment of
the potential for clinical application.
Importantly, we have shown in this transgenic murine
model of NF2 that spontaneous schwannomas are highly
infectable with HSV vectors, which can serve as a platform
for therapeutic interventions. The vector tested in this study
is a replication-conditional virus bearing the viral thymidine
kinase ( tk ) gene, which has already been shown to have
therapeutic efficacy in mouse models of gliomas [26] and
has formed the basis of a phase I clinical trial in human
glioblastoma patients [40]. hrR3 has a mutated ribonucleo-
tide reductase gene, so that this vector replicates selectively
in dividing cells with high levels of endogenous ribonucleo-
tide reductase, such as tumor cells [41]. hrR3 also encodes
the HSV-tk gene, which can convert the prodrug, ganciclo-
vir, into a nucleoside analogue that is toxic to dividing cells,
resulting in selective generation of a chemotherapeutic drug
in the tumor. Thus, addition of ganciclovir to hrR3- infected
cells can enhance the ability of hrR3 to destroy tumor cells
[25,26]. Although it is not known if the replication rate of
these schwannomas will support virus propagation or tk /
ganciclovir killing, still the HSV vectors can serve to deliver
therapeutic genes to these tumors.
We will be evaluating the therapeutic efficacy of HSV
recombinant hrR3 vectors combined with ganciclovir admin-
istration in schwannoma models by evaluation of tumor
volume over time and of tumor-selective viral replication by
histochemistry of the lacZ reporter. The humane advantages
of this type of gene therapy are that it is carried out by direct
injection of tumor masses rather than invasive surgery, and
that vectors, transgene products, and prodrugs have es-
sentially no toxicity to normal tissue, and hence, they should
have minimal morbidity to patients. If these vectors prove
effective in reducing schwannoma volume, this treatment
could replace current surgical interventions, which frequently
result in damage to critical nerve functions.
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